Titan Pharmaceuticals, Inc. (de)
TTNP
Market Cap$6.69M
Close$
$6.22
11.4% downside
Current Fair Value
11.4% downsideOvervalued by 11.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $6.69 Million |
|---|---|
| Enterprise Value | $431,736.00 |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-7.41 |
| Beta | 0.0 |
| Outstanding Shares | 914,234 |
| Avg 30 Day Volume | 12,338 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -1.2 |
|---|---|
| PEG | 5.17 |
| Price to Sales | - |
| Price to Book Ratio | 1.0 |
| Enterprise Value to Revenue | 2.35 |
| Enterprise Value to EBIT | -0.06 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 1.16 |
| Debt to Equity | 0.08 |
Revenue Sources
No data
ESG Score
No data
About Titan Pharmaceuticals, Inc. (de)
12 employeesTitan Pharmaceuticals, Inc., based in South San Francisco, CA, is a development stage company developing proprietary therapeutics with its ProNeura® long-term, continuous drug delivery technology. The ProNeura technology has the potentia...